Age-Associated Risk of Liver-Related Adverse Drug Reactions.
adverse drug reaction
hepatotoxicity
older adults
pharmacovigilance
relative risk
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
12
2021
accepted:
15
02
2022
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
5
4
2022
Statut:
epublish
Résumé
Aging population is generally considered more sensitive to adverse drug reactions (ADRs). Yet, big data-based quantitative evidence currently does not exist to support this concept. This study aims to investigate age-associated risks of liver-related ADR (L-ADR). Spontaneous reporting data from 2012 to 2016 were retrieved from the China National ADR Monitoring System. The risk ratio (RR) was used to quantify the relative risk of L-ADR of each age group. The reporting odds ratio (ROR) was used to quantify the correlation with the risk of L-ADR of each drug category or drug in older adults. Totally, 64,702 L-ADR reports were retrieved, covering ages from 1 to 116, with a median age of 49. The RR values increased exponentially with the increase of age, which indicates that the relative risk of L-ADR increased by 33% for every 10-year increase in age. The age cutoff point for relative high risk of L-ADR was estimated at 52.0 years old (RR = 1). In 17 categories composed of 270 drugs, the top 3 drug categories with a high correlation to the risk of L-ADR in older adults were antiarrhythmic (ROR, 5.75; 95% CI: 4.45-7.42), antilipemic (ROR, 4.77; 95% CI: 4.53-5.02), and antihypertensive (ROR, 2.97; 95% CI: 2.59-3.41). This research illustrates quantitatively that aging is a potential risk factor for L-ADR, with a 33% increase in relative risk for every 10-year increase in age. Risk management should be addressed for older adults when those drugs with a high correlation to the risk of L-ADR are used.
Identifiants
pubmed: 35372391
doi: 10.3389/fmed.2022.832557
pmc: PMC8968752
doi:
Types de publication
Journal Article
Langues
eng
Pagination
832557Informations de copyright
Copyright © 2022 Han, Guo, Xiong, Ge, Jing, Niu, Zhao, Bai, Song, Xiao and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Geriatr. 2020 Sep 14;20(1):346
pubmed: 32928134
Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):519-23
pubmed: 15317031
Gastroenterology. 2010 Jun;138(7):2246-59
pubmed: 20394749
Ann Intern Med. 2002 Dec 17;137(12):947-54
pubmed: 12484709
Aging Clin Exp Res. 2004 Aug;16(4):319-25
pubmed: 15575127
Neurol Ther. 2019 Dec;8(2):491-504
pubmed: 31098888
Gastroenterology. 2019 Jun;156(8):2230-2241.e11
pubmed: 30742832
Hepatology. 2009 Jun;49(6):2001-9
pubmed: 19475693
J Hepatol. 2015 Aug;63(2):503-14
pubmed: 25912521
J Clin Epidemiol. 1992 Oct;45(10):1177-84
pubmed: 1474414
Regul Toxicol Pharmacol. 2018 Apr;94:101-107
pubmed: 29407200
J Clin Epidemiol. 1993 Nov;46(11):1323-30
pubmed: 8229110
Lancet Gastroenterol Hepatol. 2020 Sep;5(9):862-874
pubmed: 32818465
Psychiatr Pol. 2016 Oct 31;50(5):1015-1026
pubmed: 27992893
Clin Liver Dis. 2017 Feb;21(1):1-20
pubmed: 27842765
Curr Gastroenterol Rep. 2013 Jan;15(1):299
pubmed: 23250699
Clin Med (Lond). 2016 Dec;16(Suppl 6):s104-s109
pubmed: 27956449
Ther Umsch. 2015 Jun;72(6):397-403
pubmed: 26098190
Cureus. 2020 Aug 26;12(8):e10047
pubmed: 32983737
Ther Adv Drug Saf. 2010 Dec;1(2):65-77
pubmed: 25083196
Curr Drug Metab. 2018;19(10):830-838
pubmed: 29788883
Hepatology. 2016 Feb;63(2):590-603
pubmed: 26517184
J Clin Epidemiol. 1993 Nov;46(11):1331-6
pubmed: 8229111
Hepatol Res. 2009 Jun;39(6):546-52
pubmed: 19254343
Neurology. 2005 Oct 25;65(8):1179-83
pubmed: 16247043
Transplant Proc. 2016 May;48(4):1115-8
pubmed: 27320569
Clin Pharmacol Ther. 2021 Apr;109(4):1147-1158
pubmed: 33179256
Nat Rev Drug Discov. 2005 Jun;4(6):489-99
pubmed: 15931258